Adrian is a Managing Director at PharmaVentures in Oxford and has been with the company since 2007. He has over 30 years experience in the pharmaceutical, biotechnology and diagnostics sectors. At PharmaVentures he has led multiple consultancy, licensing and M&A mandates. Key deals he has been involved in include Yuhan’s licensing of Lazertinib to Janssen, the transactions between MedGenesis and Pfizer, Esteve and Mundipharma, and M&A for Vital foods and Mundipharma, a UK diagnostics business acquisition by Bruker and the sale of NanoSight to Spectris plc.

Furthermore,  Adrian has led and advised on numerous licensing, M&A and fundraising deals including the sales of multiple diagnostics businesses, fundraising from China for a UK oncology business and licensing of assets to major pharmaceutical companies. He also provides strategic advice to a range of companies. Currently his activities are centred around advising companies in Korea, Europe and North America.

Adrian has over 30 years industry experience initially as a PhD scientist at Celltech and subsequently holding senior positions at Johnson & Johnson and Acumen Bioscience whilst crossing into the commercial & consultancy sector with Execute Technologies. Adrian holds a PhD in immunochemistry from Oxford and a BSc in biochemistry

Specialties: Licensing, M&A, Business Development, Fundraising, Strategic Advisory, Deal Negotiation and valuations.

Register to receive up-to-date information and advice on tax developments within your industry.